Singapore – Luminicell, a biotechnology company pioneering next-generation fluorescent imaging reagents, is pleased to announce a new distribution agreement with MediLumine, a Canadian-based leader in preclinical imaging technologies. Through this partnership, MediLumine will distribute Luminicell’s portfolio of advanced imaging probes, including Vascular Tracker™ and Cellaris™, across the regions of North America and Europe.
The collaboration combines Luminicell’s ultra-bright, biocompatible fluorescent nanoparticles with MediLumine’s high-performance PRISM and PRISM SWIR imaging systems. Together, the two platforms enable powerful new applications in preclinical research, including long-term tracking of stem cells and immune cells, deep-tissue vascular imaging, and optical angiography in the shortwave infrared (SWIR) range.
Luminicell’s fluorescent probes are 10 times brighter, highly photostable, and biocompatible. They require no genetic modification or transfection, making them ideal for longitudinal studies in both in vitro and in vivo models. When used with MediLumine’s systems, researchers can achieve greater imaging precision and generate deeper biological insights across a wide range of disease models.
“Luminicell’s products are a perfect complement to our PRISM and PRISM SWIR systems,” said Stephen Marchant, founder of MediLumine. “We are proud to offer our customers an expanded set of tools that enhance image quality and accelerate preclinical discoveries.”
This strategic partnership reflects Luminicell’s continued commitment to supporting the global life sciences community with high-performance, accessible imaging solutions.
About MediLumine
MediLumine is a Canadian provider of optical imaging systems and reagents for preclinical research. Its PRISM and PRISM SWIR platforms support real-time, high-sensitivity imaging from visible to shortwave infrared wavelengths, helping researchers study disease mechanisms and evaluate therapeutic responses more effectively.
About Luminicell
Luminicell, a wholly owned subsidiary of Nanolumi Pte Ltd, is a Singapore-based biotechnology company developing advanced fluorescent probes for live-cell, deep-tissue imaging, and diagnostic applications. Its patented encapsulation platform and Aggregation-Induced Emission (AIE) molecular design enable next-generation lipid nanoparticles that offer exceptional brightness, stability, and imaging depth for both research and clinical applications.